MétaCan
Menu
← Back to cohort
Record W2745096287 · doi:10.21608/resoncol.2013.451

Zoledronic Acid in Breast Cancer Patients with Bone Metastasis

2013· article· en· W2745096287 on OpenAlexaboutno aff
Abdel Halim El Sherbiny, W. El-Sadda

Bibliographic record

VenueResearch in Oncology · 2013
Typearticle
Languageen
FieldMedicine
TopicBone health and treatments
Canadian institutionsnot available
Fundersnot available
KeywordsZoledronic acidBreast cancerBone metastasisOncologyMedicineInternal medicineMetastasisCancerCancer research

Abstract

fetched live from OpenAlex

Background: Zoledronic acid is a nitrogen containing bisphosphonate that has been proven to reduce osteoporosis and cancer induced osteolysis. Zoledronic acid has been the treatment of choice for the prevention of skeletal complications of bone metastasis (Pain, Pathological fracture) in patients with breast cancer, which have significant impact on the quality of life of patien ts.The aim of the study is to evaluate the efficacy and tolerability of zoledronic acid in improving pain scoreand quality of life in patients with bone metastasis secondary to breast cancer.Materials & Methods: 150 patients with bone metastasis and pathologically confirmed carcinoma of the breast with ECOG PS 0-2 and adequate renal function during the period between January 2007 and January 2009 were enrolled. Treatment consisted of zoledronic acid 4 mg IV over 15 minutes repeated every 3-4 weeks concurrently with chemotherapy and/or hormonal therapy or radiotherapy if treatment was needed.Zoledronic acid was administrated continuously until worsening in the performance status, Progressionof the disease or severe adverse events. Pain was evaluated by the present pain intensity from McGill Melzack (PP1) questionnaire, quality of life (QOL) was assessed with functional assessment of cancer therapy (FACT) questionnaire.Results: The median age was 48 years (range: 30 -65 years) median PS was 1, extent of disease (metastasis): 60 patients (40%) had only one bone metastatic site and 30 patients (20%) had more than 3 bone metastatic sites. The average number of administrated cycles was 12 cycles (Range 6-50) and the average accumulated dose was 48 mg (24-200), 75 patients (50%) received treatment continuously for 2 years. The calcium and creatinine serum levels were assessed before each infusion. Five patients (3.3%) developed hypocalcaemia (calcium < 8 mg/dl) and 2 patients (1.3%) experienced a significant increase in serum creatinine (> 3 mg/dl), 12 patients (8%) had an increase of pain after first infusion of Zoledronic acid. The rate of objective reduction in pain with zoledronic acid was 48%. The improvement of qualityof Life occu red in 75 patients (50%).Conclusion: Zoledronic acid is an effective, well tolerated and easily administrated bisphosphonate with evidence of activity in the treatment of bone metastasis from breast cancer. Zoledronic acid significantly improves quality of life and pain score.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.067
GPT teacher head0.446
Teacher spread0.379 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2013
Admission routes1
Has abstractyes

Explore more

Same venueResearch in Oncology→Same topicBone health and treatments→French-language works237,207→